https://www.selleckchem.com/pr....oducts/brefeldin-a.h
Among patients with MM treated by bortezomib, CD27+CD56+ patients show better prognosis than non-CD27+CD56+ patients. The prognosis of patients with 3 risk factors of β2-MG and serum calcium concentration above the critical value and non-CD27+CD56+ expression is very poor, and clinical trials or hematopoietic stem cell transplantation or other treatment measures should be given as soon as possible. To investigate the effect of complement C3 on the prognosis of patients with multiple myeloma (MM), and to establish a predictive model
Like
Comment
Share
